DLX1 and cancer: All of our eight candidate genes showed statistically significantly different expression between normal/benign prostate and malignant PCa sample groups, low versus high Gleason grade tumors (PLA2G7), PSA relapse versus no relapse (SPON2), and low versus high TNM stages (CACNA1D and DLX1).